Previous 10 | Next 10 |
Consistent reduction in HBV DNA demonstrated with higher inarigivir doses including in high viral burden HBeAg-positive patients 26% HBsAg responder population for all inarigivir doses showed mean HBsAg change of 0.8log 10 with a range of 0.5log 10 - 1.4log 10 Inarigivir 400mg ...
HOPKINTON, Mass., April 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will host a co...
Full inarigivir (IRIG) 200mg cohort results to be presented as a late breaker oral presentation at General Session II and Award Ceremony I Poster presentation to describe the antiviral activity of IRIG in HBV clinical isolates consisting of nucleoside/CpAM-resistant variants ...
HOPKINTON, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Nezam Afdhal...
Spring Bank Pharmaceuticals (SBPH) Q4 2018 Earnings Conference Call March 11, 2019 08:00 ET Company Participants Jon Freve - CFO Martin Driscoll - President &CEO Conference Call Participants Mari Cross - Jeffries Ted Tenthoff - Piper Jaffray Katherine Xu - William Bla...
The following slide deck was published by Spring Bank Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more ...
Spring Bank Pharma (NASDAQ: SBPH ): Q4 GAAP EPS of -$0.37 beats by $0.14 . More news on: Spring Bank Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Conference Call to be Held at 8:00 am Eastern Time Inarigivir Late-Breaker Abstract Accepted for Oral Presentation at EASL The International Liver Congress 2019 HOPKINTON, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage ...
HOPKINTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will host...
HOPKINTON, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced the appointment of...
News, Short Squeeze, Breakout and More Instantly...
Spring Bank Company Name:
SBPH Stock Symbol:
NASDAQ Market:
F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals To Commence Trading November 23 on Nasdaq: FSTX PR Newswire CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 CAMBRIDGE, England and CAMBRIDGE, Mass. , Nov. 20, 2020 /PRN...
CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics 1-for-4 Reverse Stock Split to be Effective November 23, 2020 PR Newswire HOPKINTON, Mass., Nov. 20, 2020 HOPKINTON, Mass. , Nov. 20, 2020 /PRNe...
HOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stock...